tiprankstipranks
RenovoRx Struggles to Avoid Nasdaq Delisting Amid Leadership Changes
Company Announcements

RenovoRx Struggles to Avoid Nasdaq Delisting Amid Leadership Changes

RenovoRx (RNXT) has released an update.

Don't Miss Our Christmas Offers:

RenovoRx, Inc. is on the brink of being delisted from The Nasdaq Capital Market for failing to meet the minimum stockholders’ equity requirement. Despite receiving an extension until February 19, 2024, to resolve the issue, the company was still non-compliant as of the notice date. RenovoRx intends to request a hearing to postpone delisting and will present plans to regain compliance, buoyed by a recent private placement that raised $6.1 million. While the company is optimistic about meeting the requirements, there is no certainty that it will achieve compliance in time to avoid delisting.

For further insights into RNXT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyRenovoRx announces SCRI Oncology partners enrolling patients for trial
TheFlyRenovoRx receives first purchase orders for FDA-cleared RenovoCath
TheFlyRenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App